Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

Phase 3 study to evaluate the effiacay and safety of YYC506

Phase 3 study to evaluate the effiacay and safety of YYC506 in patients with complex dyslipidemia where LDL-C is properly controlled but TG and HDL-C levels are not regulated by Atorvastatin alone.

Inclusion Criteria:

• A man or woman over 19 years old.
• LDL-C properly controlled, TG, HDL-C is not properly controlled
• Sign on ICF prior to study participation

Exclusion Criteria:

• History of Fibromyalgia, Myopathy etc (CK ≥ 2XULN)
• Uncontrolled hypo-thyroidism (TSH≥1.5XULN)
• Severe renal impairemnet (Creainine clearance < 30mL/min) etc.